Search results
Results from the WOW.Com Content Network
NEW YORK (Reuters) -Sanofi's chief executive, Paul Hudson, said in an interview on Monday that the company is poised for strong growth from a variety of new drugs and is not facing imminent ...
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York.The company was founded in 1988. [2] Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company branched out into the study of both cytokine and tyrosine kinase receptors, which gave rise to their first product, which is a ...
The company produces two-thirds of its products at its Chattanooga production facilities with the remaining produced by third-party producers. The company is a subsidiary of the French multinational pharmaceutical company Sanofi. The company’s brands are sold nationally through mass merchandiser, drug and food retailers.
-The U.S. Food and Drug Administration said on Friday it has approved the use of a drug combination along with Sanofi's Sarclisa infusion as a treatment for certain types of newly diagnosed ...
The company was reportedly the center of a bidding war between Amgen, Johnson & Johnson and Sanofi. [18] In May 2023, the Federal Trade Commission said it would sue to block the deal in an attempt to control drug prices. [17] [19] [20] The acquisition was completed in October 2023 after mutually resolving the litigation. [5]
Melinta Therapeutics, founded in 2000 as Rib-X Pharmaceuticals, is an American publicly traded biopharmaceutical firm that focuses on the design and development of novel broad-spectrum antibiotics for the treatment of antibiotic-resistant infections in hospital settings.
At the time of the announcement, the treatment Dupixent from Sanofi and Regeneron was the only alternative. [43] In May 2024, Takeda announced it would be laying off 641 employees based in Massachusetts between July 2024 and March 2025 as part of a restructuring. It was expected to affect 495 people based in Cambridge and 146 people in ...
Sanofi quoted Houman Ashrafian, its head of research and development, as saying that it "represents an unprecedented breakthrough as a potential first-in-disease treatment option with clinically ...